Argus lowered the firm’s price target on Thermo Fisher (TMO) to $470 from $620 but keeps a Buy rating on the shares. Excluding the academic and government sector, the company’s end market conditions are improving as the biopharma industry develops new biologic medicines, the analyst tells investors in a research note. Thermo Fisher is also navigating headwinds arising from trade tariffs and policy changes from the U.S. administration, Argus adds.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Thermo Fisher price target lowered to $605 from $650 at Scotiabank
- 3 Best Stocks to Buy Now, 4/25/2025, According to Top Analysts
- Thermo Fisher’s Strategic Resilience Amid Macroeconomic Challenges: A Buy Recommendation
- Thermo Fisher price target lowered to $550 from $678 at Morgan Stanley
- Thermo Fisher price target lowered to $500 from $715 at UBS
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue